Research programme: dyslipidaemia oral therapeutics - Cerenis TherapeuticsAlternative Names: HDL receptor enhancer
Latest Information Update: 16 Jul 2016
At a glance
- Originator Cerenis Therapeutics
- Class Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; GPR109A receptor agonists; GPR109B receptor agonists; HMG-CoA reductase inhibitors; Lipoprotein receptor agonists; Nitric oxide stimulants; Platelet aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dyslipidaemias in Unknown (PO)